Effects of Adding Semaglutide to Basal-Bolus or Mixed Insulin Therapy: A Retrospective Chart Review
Main Article Content
Keywords
Semaglutide, Basal Insulin, Bolus Insulin, T2DM, Saudi Arabia
Abstract
Objective: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has beneficial effects when incorporated into basal insulin therapy. Despite mounting evidence from diverse geographical regions supporting its efficacy in more intricate insulin regimens for patients with type 2 diabetes (T2DM), real-world data from our region remains scarce. This study aims to assess the impact of adding Semaglutide to the basal-bolus or mixed insulin therapy over a 12-month period on glycated hemoglobin (HbA1c), weight, and total daily dose (TDD) of insulin. Methods: A retrospective chart review was conducted at a military medical center in Riyadh from January 2021 to September 2022. The study included all adult patients with T2DM who experienced clinical benefit from the addition of Semaglutide to basal-bolus or mixed insulin therapy during this timeframe. Measurements of HbA1c, weight, and TDD were obtained at baseline, 3, 6, and 9 months. Descriptive statistics and one-way ANOVA tests were utilized for statistical analysis. Results: The study cohort comprised 152 patients, of whom 105 (69.1%) were female, with a mean age of 57.7+11.4 years. There was a significant reduction in mean HbA1c levels from 9.32 at baseline to 8.62, 8.28, and 8.36 at three, six, and nine months, respectively (p-value <0.001). Moreover, mean weight in kilograms (kg) decreased from 94.8 kg at baseline to 93.54, 92.46, and 91.94 kg at three, six, and nine months, respectively (p-value > 0.005). Conclusion: This study demonstrates that the addition of Semaglutide to the current treatment regimen of patients with T2DM leads to improvements in HbA1c levels, accompanied by observed reductions in weight over nine months in individuals utilizing basal-bolus or mixed insulin therapy. Further studies with extended follow-up periods are warranted to validate these findings.
References
of Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 2020, 21, 6275, doi:10.3390/ijms21176275
2. Padhi, S.; Nayak, A.K.; Behera, A. Type II Diabetes Mellitus: A Review on Recent Drug Based Therapeutics. Biomed. Pharmacother.
2020, 131, 110708, doi:10.1016/j.biopha.2020.110708.
3. Ortiz-Martínez, M.; González-González, M.; Martagón, A.J.; Hlavinka, V.; Willson, R.C.; Rito-Palomares, M. Recent Developments
in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus. Curr. Diab. Rep. 2022, 22, 95–115, doi:10.1007/s11892-
022-01453-4.
4. American Diabetes Association Professional Practice Committee 6. Glycemic Targets: Standards of Medical Care in
Diabetes—2022. Diabetes Care 2022, 45, S83–S96, doi:10.2337/dc22-s006.
5. Choi, J.G.; Winn, A.N.; Skandari, M.R.; Franco, M.I.; Staab, E.M.; Alexander, J.; Wan, W.; Zhu, M.; Huang, E.S.; Philipson, L.; et al.
First-Line Therapy for Type 2 Diabetes with Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor
Agonists: A Cost-Effectiveness Study. Ann. Intern. Med. 2022, 175, 1392–1400, doi:10.7326/m21-2941.
6. Wojtara, M.; Mazumder, A.; Syeda, Y.; Mozgała, N. Glucagon-like Peptide-1 Receptor Agonists for Chronic Weight Management.
Adv. Med. 2023, 2023, 9946924, doi:10.1155/2023/9946924.
7. Mahapatra, M.K.; Karuppasamy, M.; Sahoo, B.M. Semaglutide, a Glucagon like Peptide-1 Receptor Agonist with Cardiovascular
Benefits for Management of Type 2 Diabetes. Rev. Endocr. Metab. Disord. 2022, 23, 521–539, doi:10.1007/s11154-021-09699-
1.
8. Kalra, S.; Sahay, R. A Review on Semaglutide: An Oral Glucagon-like Peptide 1 Receptor Agonist in Management of Type 2
Diabetes Mellitus. Diabetes Ther. 2020, 11, 1965–1982, doi:10.1007/s13300-020-00894-y.
9. Pratley, R.E.; Crowley, M.J.; Gislum, M.; Hertz, C.L.; Jensen, T.B.; Khunti, K.; Mosenzon, O.; Buse, J.B. Oral Semaglutide Reduces
HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Ther. 2021, 12, 1099–1116, doi:10.1007/s13300-020-00994-9.
10. Røder, M.E. Clinical Potential of Treatment with Semaglutide in Type 2 Diabetes Patients. Drugs Context 2019, 8, 1–11,
doi:10.7573/dic.212585.
11. Wang, W.; Liu, H.; Xiao, S.; Liu, S.; Li, X.; Yu, P. Effects of Insulin plus Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in
Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Ther. 2017, 8, 727–738, doi:10.1007/
s13300-017-0282-3.
12. Gyorffy, J.B.; Keithler, A.N.; Wardian, J.L.; Zarzabal, L.A.; Rittel, A.; True, M.W. The Impact of GLP-1 Receptor Agonists on Patients
with Diabetes on Insulin Therapy. Endocr. Pract. 2019, 25, 935–942, doi:10.4158/ep-2019-0023.
13. IDF Diabetes Atlas Available online: https://diabetesatlas.org/ (accessed on 8 June 2024).
14. Alhazmi, A.; Sane, F.; Lazrek, M.; Nekoua, M.P.; Badia-Boungou, F.; Engelmann, I.; Alidjinou, E.K.; Hober, D. Enteroviruses
and Type 1 Diabetes Mellitus: An Overlooked Relationship in Some Regions. Microorganisms 2020, 8, doi:10.3390/
microorganisms8101458.
15. Alsheikh, A.; Alshehri, A.; Alzahrani, S.; Jammah, A.A.; Alqahtani, F.; Alotaibi, M.; Aldahash, R.; Alhozali, A.M.; Alsabaan, F.;
Almehthel, M.; et al. Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type
2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study. Diabetes
Ther. 2024, 15, 473–485, doi:10.1007/s13300-023-01516-z.
16. Stratton, I.M.; Adler, A.I.; Neil, H.A.; Matthews, D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C.; Holman, R.R. Association
of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational
Study. BMJ 2000, 321, 405–412, doi:10.1136/bmj.321.7258.405.
17. Rodbard, H.W.; Lingvay, I.; Reed, J.; de la Rosa, R.; Rose, L.; Sugimoto, D.; Araki, E.; Chu, P.-L.; Wijayasinghe, N.; Norwood, P.
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J. Clin. Endocrinol. Metab.
2018, 103, 2291–2301, doi:10.1210/jc.2018-00070.
18. Sassenrath, K.; Phillips, B.B.; Stone, R.H. Evaluation of GLP-1 Receptor Agonists in Combination with Multiple Daily Insulin
Injections for Type 2 Diabetes. J. Pharm. Pract. 2022, 35, 979–990, doi:10.1177/08971900211010678.
19. Lingvay, I.; Catarig, A.-M.; Frias, J.P.; Kumar, H.; Lausvig, N.L.; le Roux, C.W.; Thielke, D.; Viljoen, A.; McCrimmon, R.J. Efficacy and
Safety of Once-Weekly Semaglutide versus Daily Canagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes (SUSTAIN
8): A Double-Blind, Phase 3b, Randomised Controlled Trial. Lancet Diabetes Endocrinol. 2019, 7, 834–844, doi:10.1016/s2213-
8587(19)30311-0.
20. Kellerer, M.; Kaltoft, M.S.; Lawson, J.; Nielsen, L.L.; Strojek, K.; Tabak, Ö.; Jacob, S. Effect of Once‐weekly Semaglutide versus
Thrice‐daily Insulin Aspart, Both as Add‐on to Metformin and Optimized Insulin Glargine Treatment in Participants with Type 2
Diabetes (SUSTAIN 11): A Randomized, Open‐label, Multinational, Phase 3b Trial. Diabetes Obes. Metab. 2022, 24, 1788–1799,
doi:10.1111/dom.14765.
21. Kapitza, C.; Dahl, K.; Jacobsen, J.B.; Axelsen, M.B.; Flint, A. Effects of Semaglutide on Beta Cell Function and Glycaemic Control
in Participants with Type 2 Diabetes: A Randomised, Double-Blind, Placebo-Controlled Trial. Diabetologia 2017, 60, 1390–
1399, doi:10.1007/s00125-017-4289-0.
22. American Diabetes Association Standards of Care in Diabetes—2023 Abridged for Primary Care Providers. Clin. Diabetes 2023,
41, 4–31, doi:10.2337/cd23-as01.
23. Lind, M.; Hirsch, I.B.; Tuomilehto, J.; Dahlqvist, S.; Ahrén, B.; Torffvit, O.; Attvall, S.; Ekelund, M.; Filipsson, K.; Tengmark, B.-O.;
et al. Liraglutide in People Treated for Type 2 Diabetes with Multiple Daily Insulin Injections: Randomised Clinical Trial (MDI
Liraglutide Trial). BMJ 2015, h5364, doi:10.1136/bmj.h5364.
24. Sheffield, C.; Kane, M.; Busch, R.; Bakst, G.; Abelseth, J.; Hamilton, R. Safety and Efficacy of Exenatide in Combination with
Insulin in Patients with Type 2 Diabetes Mellitus. Endocr. Pract. 2008, 14, 285–292, doi:10.4158/ep.14.3.285.
25. Ehrhardt, N.; Fazeli, S.; Rao, S.; Amdur, R. Use of Premixed Insulin, Metformin, and a Glucagon-like Peptide 1 Receptor Agonist
as a Therapeutic Approach for Uncontrolled Type 2 Diabetes. Diabetes Spectr. 2020, 33, 182–189, doi:10.2337/ds19-0025.
26. Almutairi, O.O.; Alhomaid, T.A.; Alshuaibi, A.M.; Ahmad Alahmad, R.M.; Al Mardhamah, N.H.; Alamri, T. The Influence of Eating
Habits on Type 2 Diabetes in Saudi Arabia: A Systematic Review. Cureus 2023, doi:10.7759/cureus.42638.
27. Gupta, A. Metabolic and Physiological Effects of Insulin. In Understanding Insulin and Insulin Resistance; Elsevier, 2022; pp.
203–230 ISBN 9780128202340.
28. Isaacs, D.M.; Kruger, D.F.; Spollett, G.R. Optimizing Therapeutic Outcomes with Oral Semaglutide: A Patient-Centered Approach.
Diabetes Spectr. 2021, 34, 7–19, doi:10.2337/ds20-0016.
29. Chen, M.; Vider, E.; Plakogiannis, R. Insulin Dosage Adjustments after Initiation of GLP-1 Receptor Agonists in Patients with
Type 2 Diabetes. J. Pharm. Pract. 2022, 35, 511–517, doi:10.1177/0897190021993625.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.